Pressure Builds For Biosimilars To Follow Lilly’s Lead After Insulin Price Cap
Eli Lilly Will Bear The Cost Of A $35 Price Cap On All Copays For Its Insulins
Biosimilar insulin producers are facing calls to improve patient affordability after Eli Lilly implemented a $35 price cap on copays for its insulins in the private market and for the uninsured.
You may also be interested in...
IRA Drug Pricing Implications Impact Pharma Views On Deal Terms, Valuations
Pharma business development executives and venture capital investors shared their thoughts on the Inflation Reduction Act at Biocom’s Global Life Science Partnering and Investor Conference in San Diego.
Lilly’s Insulin Cost Cutting Plan: Replacing Rebates With Cost Sharing Help At Point Of Sale
Biden Administration praises Lilly for latest moves to improve affordability of insulin in private market and calls for other sponsors to follow suit. Lilly’s plan is also tactical, as manufacturers of highly-rebated drugs with serial price hikes face an increased rebate liability in Medicaid next year.
New Insulin Manufacturer For Civica
Ypsomed AG will manufacture insulin dosing injector pens for non-profit Civica. Civica has also paired up with AmerisourceBergen for generics supply chain support across the US.